Iruplinalkib after surgery for early ALK-positive lung cancer
Treatments studied
Part of Cancer clinical trials.
This study tests whether taking a pill called iruplinalkib after surgery for early-stage ALK-positive lung cancer can help keep cancer from coming back. Iruplinalkib is a type of targeted therapy that blocks cancer cells with a specific ALK gene change.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have non-small cell lung cancer that is ALK-positive (a specific genetic marker).
- Your cancer was stage IA (tumor 3 cm or smaller) and has been removed with surgery.
- You have not previously taken any ALK-targeted therapy (like alectinib or crizotinib).
- You have good organ function (heart, liver, kidneys) and a good performance status (able to do daily activities).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with alk-positive non-small cell lung cancer who are taking iruplinalkib to see how well it works and how safe it is in real life. It helps doctors learn more about the drug's effects outside of clinical trials.
This study tests a combination of two targeted medicines for people with a specific type of non-small cell lung cancer (NSCLC) that has the ALK gene change. The goal is to see if giving these drugs before surgery can shrink tumors and improve outcomes.
This study looks at whether giving a targeted therapy pill (lorlatinib) before surgery can help shrink ALK-positive lung cancer and improve outcomes. It also aims to understand why some tumors may not respond to this treatment.
This trial tests a targeted therapy pill (called iruplinalkib) given before surgery for people with a certain type of lung cancer (ALK-positive NSCLC). The goal is to see if the pill can shrink the tumor, making it easier to remove completely during surgery.
This trial is for people with advanced lung cancer whose tumors have an ALK gene change and who have already taken a medicine called lorlatinib. It tests a new drug, iruplinalkib, to see how well it works for those who stopped responding to or couldn't tolerate lorlatinib.
This study tests whether giving a new targeted pill (iruplaltinib) along with chemotherapy before surgery can help shrink tumors and improve outcomes for people with ALK-positive lung cancer. Participation involves taking study drugs, having tests, and then undergoing surgery.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.